More studies using siRNA or specific CB1 and CB2 receptor antagonists should be performed to examine whether manipulating the levels of cannabinoid receptors could be a novel pharmacological approach to treat ARMD in the future. The gene discussed is CNR1; the disease is age-related macular degeneration.